Cytotoxicity of drug-treated CD34+ cells toward K562 or Jurkat cells at an effector-to-target ratio of 40:1
| Effector cells and treatment . | Target cells (% of cytotoxicity) . | |
|---|---|---|
| K562 . | Jurkat . | |
| KG1a | 1.7 (±0.7) | 3 (±0.9) |
| KG1a + Ara-C | 24.5 (±4.3)* | 39 (±7.1)* |
| KG1a + VP-16 | 14.7 (±2.2)* | 16 (±2.8)* |
| KG1a + DNR | 0.9 (±1.2) | 0.4 (±0.9) |
| TF1 | ND | 2.6 (±1.1) |
| TF1 + Ara-C | ND | 23.5 (±4.3)* |
| TF1 + VP-16 | ND | ND |
| TF1 + DNR | ND | 1.8 (±2.2) |
| HEL | ND | 0.5 (±0.1) |
| HEL + Ara-C | ND | 23.4 (±3.5)* |
| HEL + VP-16 | ND | 21.4 (±1.7)* |
| HEL + DNR | ND | 1.1 (±0.9) |
| Effector cells and treatment . | Target cells (% of cytotoxicity) . | |
|---|---|---|
| K562 . | Jurkat . | |
| KG1a | 1.7 (±0.7) | 3 (±0.9) |
| KG1a + Ara-C | 24.5 (±4.3)* | 39 (±7.1)* |
| KG1a + VP-16 | 14.7 (±2.2)* | 16 (±2.8)* |
| KG1a + DNR | 0.9 (±1.2) | 0.4 (±0.9) |
| TF1 | ND | 2.6 (±1.1) |
| TF1 + Ara-C | ND | 23.5 (±4.3)* |
| TF1 + VP-16 | ND | ND |
| TF1 + DNR | ND | 1.8 (±2.2) |
| HEL | ND | 0.5 (±0.1) |
| HEL + Ara-C | ND | 23.4 (±3.5)* |
| HEL + VP-16 | ND | 21.4 (±1.7)* |
| HEL + DNR | ND | 1.1 (±0.9) |
KG1a, TF-1, and HEL were treated with aracytine (Ara-C; 40 μmol/L), etoposide (VP-16; 20 μmol/L), or daunorubicin (DNR; 1 μmol/L) for 24 hours. Cytotoxicity was measured by using a 4-hour nonradioactive lactate dehydrogenase-release assay. Results are the mean ± standard deviation of four independent experiments performed in triplicate. ND: not determined.
P < .05.